FibroGen Shares Resume, Down 74.3%
Portfolio Pulse from Bill Haddad
FibroGen shares resumed trading and are down 74.3% after a halt due to concerns over the company's anemia drug.
June 26, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
FibroGen's stock price has dropped 74.3% due to concerns surrounding the company's anemia drug.
FibroGen's stock price has dropped significantly due to concerns over the company's anemia drug. This news directly impacts the company's stock price and investor confidence.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100